Mepenzolate

DB04843ApprovedWithdrawnSmall moleculeAnticholinergic Agents

Mepenzolate is a postganglionic parasympathetic inhibitor that was previously approved for improving the healing of gastric ulcers, but has been discontinued. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon.

Chemical structure of Mepenzolate
Mechanism
Curator reviewed
Primary indication
For use as adjunctive therapy in the treatment of peptic ulcer.Curator reviewed · 1 structured indication
Formula / weight
C21H26NO3 · 340.436 g/mol (avg)
First approval
United States, 1956
Also known as
Mepenzolic acid

Resolves to

Compound
UNIIONW3LB39P7CAS25990-43-6ChEMBLCHEMBL524004ChEBI94411PubChem4057KEGGC07818
Clinical / RWD
RxNorm107770ATCA03AB12PharmGKBPA164746250
Structure
InChIKeyGKNPSSNBBWDAGH-UHFFFAOYSA-NSMILESC[N+]1(C)CCCC(C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
Targets
P11229CHRM1P20309CHRM3P08912CHRM5

What you can answer from here — as of October 01, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
516Drug interactionsStructured to mechanism, not free text
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
1Marketed productAcross 1 country and 1 labeller
Sign in
1ATC codeIncluding every combination product, plus 10 drug categories
Sign in
11+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Mepenzolate, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In